Bris­tol My­ers flunks front­line mul­ti­ple myelo­ma tri­al, turn­ing at­ten­tion to cell ther­a­py

Cel­gene and Bris­tol My­ers Squibb may have com­bined forces, but their lat­est mix of mul­ti­ple myelo­ma treat­ments don’t ap­pear to be a good match.

Bris­tol My­ers an­nounced that its Phase III tri­al com­bin­ing the BMS drug Em­plic­i­ti — co-de­vel­oped with Ab­b­Vie — with Cel­gene’s long-run­ning block­buster Revlim­id had failed. The cock­tail did not help first-line pa­tients hold off can­cer pro­gres­sion for longer than just Revlim­id alone. (Both treat­ment arms were al­so giv­en the steroid dex­am­etha­sone.)

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.